in this issue
EnviroTech :: Biotech
Lonza Extends Manufacturing Deal with Elusys
12:06 AM MDT | July 15, 2010 | Deepti Ramesh
Lonza says it has signed an agreement with biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ), for the scale-up and commercial production of therapeutic monoclonal antibody Anthim. Anthim is in late-stage development for the treatment of inhaled anthrax. Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the U.S., according to the new contract. The manufacturing process for Anthim was optimized for full-scale production by Lonza under an agreement signed in June 2009, and the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee